COSMIC-312, 2023 NCT03755791
atezolizumab plus cabozantinib (n=432) vs. sorafenib (n=217)
randomized controlled trial
cabozantinib plus atezolizumab
cabozantinib (orally) at 40 mg once daily, and atezolizumab intravenously at 1200 mg every 3 weeks
sorafenib
sorafenib 400 mg twice daily
mHCC - 1st line (L1)
open label
178 centres in 32 countries
P3 / PFS (cabozantinib plus atezolizumab vs sorafenib in ITT pop) and OS (c a vs s) in ITT pop / PFS (cabozantinib alone vs sorafenib in ITT pop)